<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer US</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
    <PublisherURL>http://www.springer-ny.com</PublisherURL>
  </PublisherInfo>
  <Journal OutputMedium="All">
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12032</JournalID>
      <JournalDOI>10.1007/12032.1559-131X</JournalDOI>
      <JournalPrintISSN>1357-0560</JournalPrintISSN>
      <JournalElectronicISSN>1559-131X</JournalElectronicISSN>
      <JournalTitle>Medical Oncology</JournalTitle>
      <JournalAbbreviatedTitle>Med Oncol</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</JournalSubject>
        <JournalSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</JournalSubject>
        <JournalSubject Code="SCH3307X" Priority="2" Type="Secondary">Hematology</JournalSubject>
        <JournalSubject Code="SCH4800X" Priority="3" Type="Secondary">Pathology</JournalSubject>
        <JournalSubject Code="SCH33002" Priority="4" Type="Secondary">Internal Medicine</JournalSubject>
        <SubjectCollection Code="Medicine">SC11</SubjectCollection>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume OutputMedium="All">
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>33</VolumeIDStart>
        <VolumeIDEnd>33</VolumeIDEnd>
        <VolumeIssueCount>12</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular" OutputMedium="All">
        <IssueInfo IssueType="Regular" TocLevels="0">
          <IssueIDStart>7</IssueIDStart>
          <IssueIDEnd>7</IssueIDEnd>
          <IssueArticleCount>0</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2016</Year>
              <Month>7</Month>
            </CoverDate>
            <PricelistYear>2016</PricelistYear>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>Springer Science+Business Media New York</CopyrightHolderName>
            <CopyrightYear>2016</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="s12032-016-0791-3" OutputMedium="All">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>791</ArticleID>
            <ArticleDOI>10.1007/s12032-016-0791-3</ArticleDOI>
            <ArticleCitationID>75</ArticleCitationID>
            <ArticleSequenceNumber>16</ArticleSequenceNumber>
            <ArticleTitle Language="En" OutputMedium="All">Expression level and methylation status of three tumor suppressor genes, <Emphasis Type="Italic">DLEC1</Emphasis>, <Emphasis Type="Italic">ITGA9</Emphasis> and <Emphasis Type="Italic">MLH1</Emphasis>, in non-small cell lung cancer</ArticleTitle>
            <ArticleCategory>Original Paper</ArticleCategory>
            <ArticleFirstPage>1</ArticleFirstPage>
            <ArticleLastPage>8</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>4</Day>
              </RegistrationDate>
              <Received>
                <Year>2016</Year>
                <Month>5</Month>
                <Day>9</Day>
              </Received>
              <Accepted>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>4</Day>
              </Accepted>
              <OnlineDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>10</Day>
              </OnlineDate>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>Springer Science+Business Media New York</CopyrightHolderName>
              <CopyrightYear>2016</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1" ID="Au1" ORCID="http://orcid.org/0000-0001-7602-9203">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Dorota</GivenName>
                  <FamilyName>Pastuszak-Lewandoska</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>+48422725792</Phone>
                  <Email>dorota.pastuszak-lewandoska@umed.lodz.pl</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff2" ID="Au2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Jacek</GivenName>
                  <FamilyName>Kordiak</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3" ID="Au3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Adam</GivenName>
                  <FamilyName>Antczak</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au4">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Monika</GivenName>
                  <FamilyName>Migdalska-Sęk</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au5">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Karolina</GivenName>
                  <GivenName>H.</GivenName>
                  <FamilyName>Czarnecka</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff4" ID="Au6">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Paweł</GivenName>
                  <FamilyName>Górski</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au7">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Ewa</GivenName>
                  <FamilyName>Nawrot</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au8">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Justyna</GivenName>
                  <GivenName>M.</GivenName>
                  <FamilyName>Kiszałkiewicz</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au9">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Daria</GivenName>
                  <FamilyName>Domańska-Senderowska</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au10">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Ewa</GivenName>
                  <FamilyName>Brzeziańska-Lasota</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Department of Molecular Bases of Medicine</OrgDivision>
                <OrgName>Medical University of Lodz</OrgName>
                <OrgAddress>
                  <Street>Pomorska St. no. 251, C5</Street>
                  <Postcode>92-213</Postcode>
                  <City>Lodz</City>
                  <Country Code="PL">Poland</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>Department of Chest Surgery, General and Oncological Surgery, University Hospital No. 2</OrgDivision>
                <OrgName>Medical University of Lodz</OrgName>
                <OrgAddress>
                  <City>Lodz</City>
                  <Country Code="PL">Poland</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgDivision>Department of General and Oncological Pulmonology</OrgDivision>
                <OrgName>Medical University of Lodz</OrgName>
                <OrgAddress>
                  <City>Lodz</City>
                  <Country Code="PL">Poland</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff4">
                <OrgDivision>Department of Pneumology and Allergology</OrgDivision>
                <OrgName>Medical University of Lodz</OrgName>
                <OrgAddress>
                  <City>Lodz</City>
                  <Country Code="PL">Poland</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En" OutputMedium="All">
              <Heading>Abstract</Heading>
              <Para ID="Par1">Despite therapeutic advances, lung cancer remains one of the most common causes of cancer-related death in the world. There is a need to develop biomarkers of diagnostic and/or prognostic value and to translate findings in basic science research to clinical application. Tumor suppressor genes (TSGs) represent potential useful markers for disease detection, progression and treatment target. We tried to elucidate the role of three 3p21.3 TSGs: <Emphasis Type="Italic">DLEC1</Emphasis>, <Emphasis Type="Italic">ITGA9</Emphasis> and <Emphasis Type="Italic">MLH1</Emphasis>, in non-small cell lung cancer (NSCLC). We assessed their expression pattern by qPCR in 59 NSCLC tissues and in the matched macroscopically unchanged lung tissues. Additionally, we analyzed gene promoter methylation status by methylation-specific PCR in NSCLC samples. We did not find significant correlations between gene expression and methylation. In case of <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">ITGA9</Emphasis>, expression levels were decreased in 71–78 % of tumor samples and significantly different between tumor and normal tissues (<Emphasis Type="Italic">P</Emphasis> = 0.0001). It could point to their diagnostic value. <Emphasis Type="Italic">ITGA9</Emphasis> could also be regarded as a diagnostic marker differentiating NSCLC subtypes, as its expression level was significantly lower in squamous cell carcinoma (<Emphasis Type="Italic">P</Emphasis> = 0.001). The simultaneous down-regulation of <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">ITGA9</Emphasis> was observed in 52.5 % of NSCLCs. MSPs revealed high frequencies of gene promoter methylation in NSCLCs: 84 % for <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">MLH1</Emphasis> and 57 % for <Emphasis Type="Italic">ITGA9</Emphasis>. Methylation indexes reflected moderate gene methylation levels: 34 % for <Emphasis Type="Italic">ITGA9</Emphasis>, 27 % for <Emphasis Type="Italic">MLH1</Emphasis> and 26 % for <Emphasis Type="Italic">DLEC1</Emphasis>. However, frequent simultaneous methylation of the studied genes in more than 50 % of NSCLCs suggests the possibility of consider them as a panel of epigenetic markers.</Para>
            </Abstract>
            <KeywordGroup Language="En" OutputMedium="All">
              <Heading>Keywords</Heading>
              <Keyword>Non-small cell lung cancer</Keyword>
              <Keyword>Gene expression</Keyword>
              <Keyword>Promoter methylation</Keyword>
              <Keyword>Tumor suppressor gene</Keyword>
              <Keyword>Biomarker</Keyword>
            </KeywordGroup>
          </ArticleHeader>
          <Body>
            <Section1 ID="Sec1">
              <Heading>Introduction</Heading>
              <Para ID="Par2">Lung cancer is representing 22.5 % of all cancer, as one of the leading causes of cancer deaths [<CitationRef CitationID="CR1">1</CitationRef>]. Although substantial progress has been recently achieved toward developing methods and strategies to lung cancer treatment, the survival rate of lung cancer patients is still poor. New molecular technologies used in the field of genomics, epigenomics, proteomics, metabolomics and transcriptomics greatly affect cancer-related research. Their aim is to develop biomarkers for early cancer diagnosis, prediction of potential metastases and evaluation of possible treatment and to translate selected promising findings in basic science research to clinical application [<CitationRef CitationID="CR2">2</CitationRef>].</Para>
              <Para ID="Par3">Tumor suppressor genes (TSGs) play crucial role in blocking the development of human tumors. In lung cancer, frequent loss of heterozygosity (LOH) on short arm of chromosome 3 (3p) in multiple critical regions and homozygous deletions and epigenetic modifications are observed in early cancerous stages and even in preneoplastic lesions [<CitationRef CitationID="CR3">3</CitationRef>–<CitationRef CitationID="CR5">5</CitationRef>]. This indicates the presence and significance of genes located in 3p. Indeed, LOH analyses in 3p found two frequently affected regions (FARs) within 3p21.3: LUCA (lung cancer region) in the centromeric region (3p21C) and AP20 (Alu-PCR clone 20 region) in the telomeric region (3p21T) [<CitationRef CitationID="CR6">6</CitationRef>]. These regions contain loci of multiple TSGs [<CitationRef CitationID="CR6">6</CitationRef>–<CitationRef CitationID="CR8">8</CitationRef>]. In our study, we analyzed three consecutive TSGs from AP20 region: <Emphasis Type="Italic">DLEC1</Emphasis>, <Emphasis Type="Italic">ITGA9</Emphasis> and <Emphasis Type="Italic">MLH1</Emphasis>. It should be stressed that this study was a part of a more comprehensive research project, which included TSGs also from LUCA region, namely <Emphasis Type="Italic">FUS1</Emphasis>, <Emphasis Type="Italic">NPRL2/G21</Emphasis> and <Emphasis Type="Italic">RASSF1A</Emphasis> [<CitationRef CitationID="CR9">9</CitationRef>].</Para>
              <Para ID="Par4">Cancer development is also linked with aberrant DNA methylation patterns, which can be characterized as global genome hypomethylation accompanied by regional hypermethylation [<CitationRef CitationID="CR10">10</CitationRef>]. Primary non-small cell lung cancer and NSCLC cell lines show multiple aberrantly methylated genes, including <Emphasis Type="Italic">RASSF1A</Emphasis>, <Emphasis Type="Italic">DAPK</Emphasis>, <Emphasis Type="Italic">MGMT</Emphasis>, <Emphasis Type="Italic">RARβ</Emphasis>, <Emphasis Type="Italic">TIMP3</Emphasis>, <Emphasis Type="Italic">p16</Emphasis>, <Emphasis Type="Italic">CDH1</Emphasis>, <Emphasis Type="Italic">GSTP1</Emphasis> and <Emphasis Type="Italic">p14ARF</Emphasis> [<CitationRef CitationID="CR11">11</CitationRef>–<CitationRef CitationID="CR13">13</CitationRef>]. The studies point to gene hypermethylation as a molecular biomarker in early detection of lung neoplasms (e.g., <Emphasis Type="Italic">p16</Emphasis>), or associated with late stage of lung cancer (e.g., <Emphasis Type="Italic">ASC</Emphasis>/<Emphasis Type="Italic">TMS1</Emphasis>) [<CitationRef CitationID="CR14">14</CitationRef>]. It is suggested that modified methylation patterns could be used for diagnosis, for prognosis and even for direct treatment of cancer.</Para>
              <Para ID="Par5">The pre-specified hypothesis tested in the study was altered expression and methylation status of selected TSGs (<Emphasis Type="Italic">DLEC1</Emphasis>, <Emphasis Type="Italic">ITGA9</Emphasis>, <Emphasis Type="Italic">MLH1</Emphasis>) from AP20 region in primary non-small cell lung cancer. The results of such analysis and correlation with NSCLC histotypes, tumor and patient characteristics should give an answer on the importance of these genes in lung carcinogenesis. Additionally, together with our previous findings [<CitationRef CitationID="CR9">9</CitationRef>], they will expand our knowledge on lung cancer biology and fit into the trend of recent studies looking for biomarkers in early lung carcinogenesis and cancer progression.</Para>
            </Section1>
            <Section1 ID="Sec2">
              <Heading>Materials and methods</Heading>
              <Para ID="Par6">The study has been approved by the Ethical Committee of the Medical University of Lodz, Poland, no. RNN/140/10/KE. Written informed consent was obtained from each patient.</Para>
              <Section2 ID="Sec3">
                <Heading>Lung tissue samples and patients clinical characteristics</Heading>
                <Para ID="Par7">The study was performed in the group of patients admitted to the University Clinic of Pneumology and Allergology of 1st Chair of Internal Diseases of Medical University of Lodz and in the Department of Thoracic Surgery, General and Oncologic Surgery, Medical University of Lodz, Poland, between July 2010 and March 2013. Patients, with diagnosed NSCLC, were treated by lobectomy or pneumonectomy. During the surgery, lung tissue samples (100–150 mg) were obtained from the center of primary lesion and 10 cm distant from it (the adjacent non-cancerous specimen, macroscopically unchanged). Immediately after resection, lung tissue samples were placed in a stabilization buffer RNAlater<Superscript>®</Superscript>, then divided into smaller parts (30–50 mg) for further analysis and frozen at −80 °C.</Para>
                <Para ID="Par8">The tissue samples were postoperatively histopathologically evaluated by pathologist and classified according to AJCC staging as well as TNM classification (pTNM). The final study group consisted of 59 patients (24 women and 35 men), with a mean age of 61 ± 7.62. For correlation analyses, they were divided into three groups: aged under or equal to 60 years (<Emphasis Type="Italic">n</Emphasis> = 14), 61–70 years (<Emphasis Type="Italic">n</Emphasis> = 30) and over 70 years (<Emphasis Type="Italic">n</Emphasis> = 15). The history of smoking was obtained for all patients: 54 were smokers (current smokers, <Emphasis Type="Italic">n</Emphasis> = 31, and former smokers, <Emphasis Type="Italic">n</Emphasis> = 23) and five non-smokers. For further correlation analyses, smokers were divided into two groups according to pack-year (PY) values (1 pack-year = 20 cigarettes smoked per day for 1 year): &lt;40 PYs (<Emphasis Type="Italic">n</Emphasis> = 26) and ≥40 PYs (<Emphasis Type="Italic">n</Emphasis> = 28). Based on histopathological assessments, the group of patients was subdivided in relation to NSCLC subtypes: squamous cell carcinoma (SCC, <Emphasis Type="Italic">n</Emphasis> = 34), adenocarcinoma (AC, <Emphasis Type="Italic">n</Emphasis> = 20) and large cell carcinoma (LCC, <Emphasis Type="Italic">n</Emphasis> = 5). All cases were primary tumors without chemo- or radiotherapy treatment.</Para>
              </Section2>
              <Section2 ID="Sec4">
                <Heading>RNA extraction, reverse transcription and real-time PCR</Heading>
                <Para ID="Par9">Total RNA was extracted from primary lung cancer and macroscopically unchanged lung tissues using Universal RNA Purification Kit (Eurx, Poland), according to the manufacturer’s recommendations. The quality and quantity of RNA samples was assessed in Agilent 2100 Bioanalyzer (Agilent, USA) using RNA 6000 Pico/Nano LabChip kit (Agilent Technologies, USA).</Para>
                <Para ID="Par10">Reverse transcription (RT) reactions were performed using 100 ng of total RNA and High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA). RT master mix contained: 10× RT buffer, 25× dNTP Mix (100 mM), 10× RT Random Primers, MultiScribe™ Reverse Transcriptase, RNase Inhibitor and nuclease-free water, in a total volume of 20 µl. Negative control was included in each RT reaction, containing no RNA (No RT control). RT reactions were performed in the following conditions: 10 min at 25 °C, 120 min at 37 °C, then 5 s at 85 °C and 4 °C hold.</Para>
                <Para ID="Par11">The relative expression of the studied genes was assessed in qPCRs performed in 7900HT Fast Real-Time PCR System (Applied Biosystems, USA) with RQ software (TaqMan Relative Quantification Assay software). Micro Fluidic Cards, the so-called TLDA (TaqMan<Superscript>®</Superscript> Low-Density Custom Arrays) plates, were used in qPCRs. The selected assays (Applied Biosystems, USA), preloaded on the plates, were: Hs00201098_m1 (DLEC1), Hs00979865_m1 (<Emphasis Type="Italic">ITGA9</Emphasis>), Hs00179866_m1 (MLH1) and Hs00382667_m1 (<Emphasis Type="Italic">ESD</Emphasis>) which served as a reference gene. RNA from normal lung tissue (Human Lung Total RNA, Ambion<Superscript>®</Superscript>, USA) was used as calibrator. The reaction mixture contained: 50 µl cDNA (50 ng) and 50 µl TaqMan<Superscript>®</Superscript> Universal Master Mix (Applied Biosystems, USA). For negative control, No RT control sample was used. The PCR program was as follows: initial incubation 2 min at 50 °C, AmpliTaq Gold<Superscript>®</Superscript> DNA polymerase activation at 94.5 °C for 10 min, then 40 two-step cycles 30 s at 97 °C and 60 s at 59.7 °C. Each reaction was performed in triplicate.</Para>
              </Section2>
              <Section2 ID="Sec5">
                <Heading>DNA extraction, bisulfite conversion and methylation-specific PCRs</Heading>
                <Para ID="Par12">Genomic DNA was obtained using QIAamp DNA Mini Kit (Qiagen, Germany), according to the manufacturer’s protocol. The quality and quantity of DNA was spectrophotometrically assessed (Eppendorf BioPhotometer™ plus, Germany), and DNA samples with a 260/280-nm ratio in the range 1.8–2.0 were considered as high quality and selected for further analysis.</Para>
                <Para ID="Par13">Bisulfite conversion was performed using genomic DNA (1 µg) and CpGenomeTM Turbo Bisulfide Modification Kit (Chemicon International, Millipore, USA), according to the manufacturer’s recommendations. The concentration and purity of modified DNA was spectrophotometrically estimated (Eppendorf BioPhotometer™ plus, Germany).</Para>
                <Para ID="Par14">Next, methylation-specific polymerase chain reactions (MSPs) were performed to assess methylation status of the studied genes. Primers for MSPs were designed according to the criteria described by Feltus et al. [<CitationRef CitationID="CR15">15</CitationRef>]. Promoter region sequences for the studied genes were taken from NCBI database. Then, sequences were analyzed using a computer tool (methPrimer v1.1 beta, Li Lab, Department of Urology, USCF) [<CitationRef CitationID="CR16">16</CitationRef>] that enabled the prediction of bisulfite modified sequence (with cytosines in sites of methyl cytosines and uracils in sites of unmethylated cytosines). Table <InternalRef RefID="Tab1">1</InternalRef> presents the sequences for methylated and unmethylated promoter regions of the studied genes. MSP master mix contained: 1000 ng DNA, 0.7 µM of each primer (Sigma, Germany), 2.5 µM dNTPs mix, 2.5 µM MgCl<Subscript>2</Subscript>, Hot Start AmpliTaq Gold<Superscript>®</Superscript> 360 DNA Polymerase (5U/µl), 10× Universal PCR buffer and nuclease-free water, in a total volume of 12.5 µl. PCR conditions were as follows: initial denaturation at 95 °C for 5 min, followed by 40 three-step cycles involving denaturation at 95 °C for 45 s, specific annealing temperature (see Table <InternalRef RefID="Tab1">1</InternalRef>) for 45 s and elongation at 72 °C for 1 min; the final elongation step was done at 72 °C for 10 min.<Table Float="Yes" ID="Tab1">
                    <Caption Language="En">
                      <CaptionNumber>Table 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>MSP primers (M: methylated; U: unmethylated) used in the study</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="6">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <colspec align="left" colname="c5" colnum="5"/>
                      <colspec align="left" colname="c6" colnum="6"/>
                      <thead>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Gene</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>MSP primers</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>Forward primer</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>Reverse primer</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>Product length (bp)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>Annealing temp. (°C)</SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry align="left" colname="c1" morerows="1">
                            <SimplePara>
                              <Emphasis Type="Italic">DLEC1</Emphasis>
                            </SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>M</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>GATTATAGCGATGACGGGATTC</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>ACCCGACTAATAACGAAATTAACG</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>193</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>57.5</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c2">
                            <SimplePara>U</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>AATGATTATAGTGATGATGGGATTTG</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>ACCCAACTAATAACAAAATTAACACC</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>196</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>55.0</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>
                              <Emphasis Type="Italic">ITGA9</Emphasis>
                            </SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>M</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>TTTTTGATAAGTTTTTAGATGACGT</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>ATTATTCATAACAATAATAACCACGTA</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>141</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>44.5</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1"/>
                          <entry align="left" colname="c2">
                            <SimplePara>U</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>TTTTTGATAAGTTTTTAGATGATGT</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>TATTCATAACAATAATAACCACATA</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>139</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>44.5</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>
                              <Emphasis Type="Italic">MLH1</Emphasis>
                            </SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>M</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>GGGAGGTTATAAGAGTAGGGTTAAC</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>TACCCGCTACCTAAAAAAATATACG</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>246</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>50.5</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1"/>
                          <entry align="left" colname="c2">
                            <SimplePara>U</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>GGAGGTTATAAGAGTAGGGTTAATGT</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>TACCCACTACCTAAAAAAATATACACT</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>245</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>57.5</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                  </Table>
                        </Para>
                <Para ID="Par15">In each PCR, CpGenome Universal Methylated DNA (enzymatically methylated human male genomic DNA) served as a positive methylation control and CpGenome Universal Unmethylated DNA (human fetal cell line) was used as a negative control (CHEMICON International, Millipore, USA). Blank samples with nuclease-free water instead of DNA were used as a control for PCR contamination.</Para>
                <Para ID="Par16">The products of MSPs were electrophoretically separated (2 % agarose gel) and their concentrations (ng) were spectrophotometrically estimated (for U and M DNA alleles), using DNA1000 LabChip Kit, on Agilent 2100 Bioanalyzer (Agilent Technologies, USA). For each sample, methylation index (MI) was assessed, according to the formula: peak height of methylated products/(peak height of methylated products + peak height of unmethylated product), MI = (M)/(M + U).</Para>
              </Section2>
              <Section2 ID="Sec6">
                <Heading>Statistical analysis</Heading>
                <Para ID="Par17">The results of relative expression analysis were compared between cancer and non-cancer specimens using Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test and Kruskal–Wallis test. The same nonparametric tests were applied to compare gene expression and methylation patterns between NSCLC subtypes (SCC, AC and LCC). To evaluate the relationship between gene expressions and clinicopathological parameters (patients’ age and gender, history of smoking, tumor staging according to pTNM and AJCC classifications), Spearman’s rank correlation coefficient, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test and Kruskal–Wallis test were used. Nonparametric Spearman’s criterion was used to calculate the coefficient of correlation between the levels of mRNA expression or promoter methylation for pairs of studied TSGs.</Para>
                <Para ID="Par18">
                           <Emphasis Type="Italic">P</Emphasis> values &lt;0.05 were considered statistically significant. All statistical procedures were performed using Statistica for Windows 10.0 software.</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec7">
              <Heading>Results</Heading>
              <Section2 ID="Sec8">
                <Heading>Relative expression levels of the studied TSGs</Heading>
                <Para ID="Par19">For relative expression analysis, delta–delta C<Subscript>T</Subscript> method was used, and the obtained results were presented as RQ values adjusted to the expression of <Emphasis Type="Italic">ESD</Emphasis> (endogenous control) and in relation to the expression level of calibrator (normal lung tissue), for which RQ = 1. Table <InternalRef RefID="Tab2">2</InternalRef> indicates RQ values (medians) of the studied genes and the frequency of samples with importantly decreased expression (RQ &lt; 0.5, indicating a minimum of twofold down change in gene expression level) in individual tissue groups. Among the studied genes, <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">ITGA9</Emphasis> showed decreased expression in 77.9 and 71.2 % of NSCLC samples, respectively, and <Emphasis Type="Italic">MLH1</Emphasis>—in 18.6 %. The simultaneous down-regulation of <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">ITGA9</Emphasis> was observed in 52.5 % of NSCLCs and regarding histopathological subtypes: in 76.5 % of SCCs and 15 % of ACs.<Table Float="Yes" ID="Tab2">
                    <Caption Language="En">
                      <CaptionNumber>Table 2</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Expression levels of the studied <Emphasis Type="Italic">TSGs and the frequency</Emphasis> of samples with their importantly decreased expression</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="6">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <colspec align="left" colname="c5" colnum="5"/>
                      <colspec align="left" colname="c6" colnum="6"/>
                      <thead>
                        <row>
                          <entry align="left" nameend="c3" namest="c1">
                            <SimplePara>Relative expression in the studied tissue groups</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>
                              <Emphasis Type="Italic">DLEC1</Emphasis>
                            </SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>
                              <Emphasis Type="Italic">ITGA9</Emphasis>
                            </SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>
                              <Emphasis Type="Italic">MLH1</Emphasis>
                            </SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry align="left" colname="c1" morerows="3">
                            <SimplePara>Median <Emphasis Type="Italic">RQ</Emphasis> values</SimplePara>
                          </entry>
                          <entry align="left" nameend="c3" namest="c2">
                            <SimplePara>NSCLC total group</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>0.36</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>0.68</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>1.29</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c2" morerows="1">
                            <SimplePara>NSCLC subtypes</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>SCC</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>0.31</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>0.50</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>1.21</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c3">
                            <SimplePara>NSCC</SimplePara>
                            <SimplePara>(AC; LCC)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>0.54</SimplePara>
                            <SimplePara>(0.55; 0.27)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>1.07</SimplePara>
                            <SimplePara>(1.50; 0.52)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>1.57</SimplePara>
                            <SimplePara>(1.61; 1.29)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" nameend="c3" namest="c2">
                            <SimplePara>Macroscopically unchanged lung tissue</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>1.11</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>1.50</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>1.17</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1" morerows="3">
                            <SimplePara>Frequency of <Emphasis Type="Italic">RQ</Emphasis> &lt; 0.5</SimplePara>
                          </entry>
                          <entry align="left" nameend="c3" namest="c2">
                            <SimplePara>NSCLC total group</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>56 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>35.6 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>3.4 %</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c2" morerows="1">
                            <SimplePara>NSCLC subtypes</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>SCC</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>64.7 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>50 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>5.9 %</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c3">
                            <SimplePara>NSCC</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>44 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>16 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>0 %</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" nameend="c3" namest="c2">
                            <SimplePara>Macroscopically unchanged lung tissue</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>20.3 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>1.7 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>1.7 %</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                  </Table>
                        </Para>
                <Para ID="Par20">The obtained RQ values in lung cancer tissues were correlated with histopathological NSCLC subtypes (SCC, AC, LCC), tumor staging (pTNM, AJCC), patients’ age, gender and smoking history, as well as with RQ values of the studied genes in macroscopically unchanged lung tissue samples. The expression levels of <Emphasis Type="Italic">ITGA9</Emphasis> and <Emphasis Type="Italic">MLH1</Emphasis> were significantly different between NSCLC subtypes: lower in SCC than in NSCC (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05). Presenting the exact numerical values, the median RQ values of <Emphasis Type="Italic">ITGA9</Emphasis> in SCC versus NSCC were 0.50 versus 1.50 (<Emphasis Type="Italic">P</Emphasis> = 0.0001, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test) and of <Emphasis Type="Italic">MLH1</Emphasis> were 1.21 versus 1.57 (<Emphasis Type="Italic">P</Emphasis> = 0.03, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test).</Para>
                <Para ID="Par21">For all studied genes, significant differences in expression levels were observed between tumor samples and macroscopically unchanged lung tissues (in total NSCLC group and/or in NSCLC histopathological subtypes). <Emphasis Type="Italic">DLEC1</Emphasis> expression was significantly lower in NSCLC samples (0.36 vs. 1.11, <Emphasis Type="Italic">P</Emphasis> = 0.0001, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test), as well as in NSCLC subtypes: SCC (0.31 vs. 1.13, <Emphasis Type="Italic">P</Emphasis> = 0.00002, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test) and AC (0.55 vs. 1.09 <Emphasis Type="Italic">P</Emphasis> = 0.01, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test). Similarly, <Emphasis Type="Italic">ITGA9</Emphasis> expression was significantly decreased in tumors as compared to normal lung tissues (0.68 vs. 1.50, <Emphasis Type="Italic">P</Emphasis> = 0.0001, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test) and in SCC subgroup (0.50 vs. 1.55, <Emphasis Type="Italic">P</Emphasis> = 0.0001, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test). <Emphasis Type="Italic">MLH1</Emphasis> gene revealed significantly higher expression level in NSCLC samples than in macroscopically unchanged lung tissues (1.29 vs. 1.17, <Emphasis Type="Italic">P</Emphasis> = 0.03, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test) and similarly in NSCC subgroup (1.57 vs. 1.28, <Emphasis Type="Italic">P</Emphasis> = 0.04, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test).</Para>
                <Para ID="Par22">There were not any significant correlations between expression levels of the studied genes and patients’ gender, and smoking history (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05). Regarding patients’ age, a negative correlation was found in SSC group for <Emphasis Type="Italic">DLEC1</Emphasis> (<Emphasis Type="Italic">P</Emphasis> = 0.04, Spearman’s rank correlation coefficient). In case of <Emphasis Type="Italic">MLH1</Emphasis> gene, statistically significant differences were observed between tumor stages II and III (according to AJCC classification) in SCC (1.34 vs. 1.07, <Emphasis Type="Italic">P</Emphasis> = 0.01, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test) and AC (1.19 vs. 1.82, <Emphasis Type="Italic">P</Emphasis> = 0.02, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test). No significant differences were found between tumor groups classified according to pTNM (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05).</Para>
              </Section2>
              <Section2 ID="Sec9">
                <Heading>Methylation status of the studied TSG genes</Heading>
                <Para ID="Par23">Due to DNA degradation in several samples, i.e., 10 in case of <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">MLH1</Emphasis> and 12 in case of <Emphasis Type="Italic">ITGA9</Emphasis>, the results on methylation status of the studied genes were obtained for different numbers of patients.</Para>
              </Section2>
              <Section2 ID="Sec10">
                <Heading>Qualitative assessment of TSG methylation</Heading>
                <Para ID="Par24">In all studied tumor tissue groups, the presence of unmethylated (U) and/or methylated (M) alleles was revealed after electrophoretic separation of MSP products. M alleles were observed in 57–84 % of samples, depending on the gene. The frequencies of methylated and unmethylated alleles in the studied tissue groups, for all TSGs, are summarized in Table <InternalRef RefID="Tab3">3</InternalRef>. The highest frequency of both TSG methylated alleles was observed for <Emphasis Type="Italic">ITGA9</Emphasis> (19 %); however, the same gene revealed the highest number of samples without any methylated allele (43 %). In case of <Emphasis Type="Italic">DLEC1</Emphasis>, there were 84 % of NSCLC samples with the presence of at least one methylated allele. The simultaneous presence of methylated alleles of all three genes was found in 53.5 % of NSCLC samples.<Table Float="Yes" ID="Tab3">
                    <Caption Language="En">
                      <CaptionNumber>Table 3</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Presence of methylated (M) and unmethylated (U) alleles in the studied tumor tissue groups</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="6">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="char" char="(" colname="c4" colnum="4"/>
                      <colspec align="char" char="(" colname="c5" colnum="5"/>
                      <colspec align="char" char="(" colname="c6" colnum="6"/>
                      <thead>
                        <row>
                          <entry align="left" nameend="c3" namest="c1">
                            <SimplePara>MI values in the studied tissue groups</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>
                                            <Emphasis Type="Italic">DLEC1</Emphasis> (<Emphasis Type="Italic">n</Emphasis> = 49)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>
                                            <Emphasis Type="Italic">ITGA9</Emphasis> (<Emphasis Type="Italic">n</Emphasis> = 47)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>
                                            <Emphasis Type="Italic">MLH1</Emphasis> (<Emphasis Type="Italic">n</Emphasis> = 49)</SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry align="left" colname="c1" morerows="2">
                            <SimplePara>
                                            <Emphasis Type="Italic">MI</Emphasis> = 1</SimplePara>
                            <SimplePara>(both M alleles)</SimplePara>
                          </entry>
                          <entry align="left" nameend="c3" namest="c2">
                            <SimplePara>NSCLC total group</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>1 (2 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>9 (19 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>5 (10 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c2" morerows="1">
                            <SimplePara>NSCLC subtypes</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>SCC</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>1 (3 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>6 (22 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>2 (7 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c3">
                            <SimplePara>NSCC</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>0 (0 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>3 (15 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>3 (15 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1" morerows="2">
                            <SimplePara>
                                            <Emphasis Type="Italic">MI</Emphasis> = 0</SimplePara>
                            <SimplePara>(both U alleles)</SimplePara>
                          </entry>
                          <entry align="left" nameend="c3" namest="c2">
                            <SimplePara>NSCLC total group</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>8 (16 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>20 (43 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>8 (16 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c2" morerows="1">
                            <SimplePara>NSCLC subtypes</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>SCC</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>3 (10 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>10 (37 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>5 (17 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c3">
                            <SimplePara>NSCC</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>5 (26 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>10 (50 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>3 (15 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1" morerows="2">
                            <SimplePara>0 &lt; <Emphasis Type="Italic">MI</Emphasis> &lt; 1</SimplePara>
                            <SimplePara>(M and U allele)</SimplePara>
                          </entry>
                          <entry align="left" nameend="c3" namest="c2">
                            <SimplePara>NSCLC total group</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>40 (82 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>18 (38 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>36 (74 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c2" morerows="1">
                            <SimplePara>NSCLC subtypes</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>SCC</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>26 (87 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>11 (41 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>22 (76 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c3">
                            <SimplePara>NSCC</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c4">
                            <SimplePara>14 (74 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c5">
                            <SimplePara>7 (35 %)</SimplePara>
                          </entry>
                          <entry align="char" char="(" colname="c6">
                            <SimplePara>14 (70 %)</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                  </Table>
                        </Para>
              </Section2>
              <Section2 ID="Sec11">
                <Heading>Quantitative assessment of TSG methylation (methylation index)</Heading>
                <Para ID="Par25">Based on spectrophotometric estimation (Agilent 2100 Bioanalyzer), fluorescence units (FU) of MSP products were quantified (ng/µl), according to DNA size marker (DNA ladder, Agilent Technologies, USA), and MI was calculated for each gene in all tissue samples. MIs indicated gene methylation level, which in NSCLC samples was 26–34 %, depending on the gene. Table <InternalRef RefID="Tab4">4</InternalRef> summarizes TSG methylation levels in the studied lung cancer tissue groups.<Table Float="Yes" ID="Tab4">
                    <Caption Language="En">
                      <CaptionNumber>Table 4</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>MI values (%) of the studied TSGs</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="5">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="char" char="." colname="c3" colnum="3"/>
                      <colspec align="char" char="." colname="c4" colnum="4"/>
                      <colspec align="char" char="." colname="c5" colnum="5"/>
                      <thead>
                        <row>
                          <entry align="left" colname="c1" morerows="1"/>
                          <entry align="left" colname="c2" morerows="1">
                            <SimplePara>NSCLC total group</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>DLEC1</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>ITGA9</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>MLH1</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c3">
                            <SimplePara>26 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>34 %</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>27 %</SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry align="left" colname="c1" morerows="2">
                            <SimplePara>NSCLC subtypes</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>SCC</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c3">
                            <SimplePara>30</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c4">
                            <SimplePara>37</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c5">
                            <SimplePara>23</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c2">
                            <SimplePara>NSCC</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c3">
                            <SimplePara>19</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c4">
                            <SimplePara>30</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c5">
                            <SimplePara>33</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c2">
                            <SimplePara>AC</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c3">
                            <SimplePara>20</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c4">
                            <SimplePara>25</SimplePara>
                          </entry>
                          <entry align="char" char="." colname="c5">
                            <SimplePara>36</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                  </Table>
                        </Para>
                <Para ID="Par26">Statistical analysis did not reveal any correlations between gene methylation levels in NSCLC or its histopathological subtypes. Concerning tumor histopathological characteristics, the following correlations were found: <Emphasis Type="Italic">DLEC1</Emphasis> methylation level in SCC group was significantly higher in T2 versus T3/T4 tumors (<Emphasis Type="Italic">P</Emphasis> = 0.017, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test); in NSCC group, <Emphasis Type="Italic">DLEC1</Emphasis> was significantly higher methylated in stage I vs stage II tumors (<Emphasis Type="Italic">P</Emphasis> = 0.04, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test); in SCC group, <Emphasis Type="Italic">MLH1</Emphasis> methylation status was significantly higher in stage I/II vs stage III tumors (<Emphasis Type="Italic">P</Emphasis> = 0.02, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test).</Para>
                <Para ID="Par27">Regarding patients’ characteristics, statistically significant correlations between <Emphasis Type="Italic">DLEC1</Emphasis> methylation status and patient age were found in NSCLC group (patients aged ≤60 vs. 61–70 years, <Emphasis Type="Italic">P</Emphasis> = 0.02; 61–70 vs. &gt;70 years, <Emphasis Type="Italic">P</Emphasis> = 0.001, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> tests), in AC subgroup (≤60 vs. 61–70 years, <Emphasis Type="Italic">P</Emphasis> = 0.03, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test) and in NSCC subgroup (≤60 vs. 61–70 years, <Emphasis Type="Italic">P</Emphasis> = 0.02, Mann–Whitney <Emphasis Type="Italic">U</Emphasis> test). In all those groups, the highest methylation level of <Emphasis Type="Italic">DLEC1</Emphasis> was observed in patients aged 61–70 years.</Para>
              </Section2>
              <Section2 ID="Sec12">
                <Heading>Correlation between gene expression level and methylation status</Heading>
                <Para ID="Par28">The decreased expression of <Emphasis Type="Italic">DLEC1</Emphasis> with simultaneous promoter methylation was found in 63.3 % of NSCLC samples, in case of <Emphasis Type="Italic">ITGA9</Emphasis>—in 40.4 % and in case of <Emphasis Type="Italic">MLH1</Emphasis>—in 6.1 %.</Para>
                <Para ID="Par29">We did not find negative correlations between the RQ and MI values of the studied genes. Positive correlation was revealed for <Emphasis Type="Italic">MLH1</Emphasis> (<Emphasis Type="Italic">P</Emphasis> = 0.03, Spearman’s rank correlation coefficient, <Emphasis Type="Italic">rs</Emphasis> = 0.31).</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec13">
              <Heading>Discussion</Heading>
              <Para ID="Par30">Lung cancer is recognized as a complex and heterogeneous disease, not only at clinical but also at biochemical and molecular level, considering metabolites, proteins and genes. There is a need to collect findings from multiple disciplines into one model that will integrate genomic and clinical features of NSCLC to improve the understanding of this disease.</Para>
              <Para ID="Par31">In our study, we analyzed the expression levels of three genes located in AP20 region in 3p21.3, which is frequently disturbed in lung cancers. We also analyzed gene expression levels in macroscopically unchanged lung tissue, surrounding the primary lesion. The studied genes, <Emphasis Type="Italic">DLEC1</Emphasis>, <Emphasis Type="Italic">ITGA9</Emphasis> and <Emphasis Type="Italic">MLH1</Emphasis>, are functional TSGs. However, the reports on their expression in lung cancers are ambiguous and the mechanisms underlying their decreased expression remain unclear. We looked for gene promoter hypermethylation as the possible epigenetic mechanism of gene silencing. Epigenetic alterations are regarded as equally important as genetic lesions in the carcinogenesis and cancer progression [<CitationRef CitationID="CR10">10</CitationRef>]. As found in several studies, aberrant gene promoter methylation represents an ideal candidate for diagnostic and prognostic markers in cancer [<CitationRef CitationID="CR17">17</CitationRef>].</Para>
              <Para ID="Par32">In our analysis, among the studied genes, the highest frequency of decreased expression was found for <Emphasis Type="Italic">DLEC1</Emphasis>, followed by <Emphasis Type="Italic">ITGA9</Emphasis>. <Emphasis Type="Italic">DLEC1</Emphasis> was importantly decreased in 56 % of NSCLC samples, more often in SCC subtype (in nearly 65 %) than in NSCC (44 %). Similarly, <Emphasis Type="Italic">ITGA9</Emphasis> showed lower expression in SCC samples. The simultaneous down-regulation of <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">ITGA9</Emphasis> was observed in more than 50 % of total NSCLCs and in nearly 77 % of SCCs. Methylation frequencies of all studied genes in total NSCLC samples were 57–84 %, with equally higher methylation frequency for <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">MLH1</Emphasis>. The simultaneous methylation of all three genes was found in 53.5 % of NSCLC samples.</Para>
              <Para ID="Par33">
                        <Emphasis Type="Italic">DLEC1</Emphasis> (<Emphasis Type="Italic">deleted in lung and esophageal cancer 1</Emphasis>), as a TSG, suppresses tumor growth or reduces the invasiveness of cancer cells. <Emphasis Type="Italic">DLEC1</Emphasis> is expressed in normal lung or kidney tissue, while in tumors gene expression is disturbed [<CitationRef CitationID="CR8">8</CitationRef>, <CitationRef CitationID="CR18">18</CitationRef>]. Decreased <Emphasis Type="Italic">DLEC1</Emphasis> expression—on mRNA and protein level—was observed in lung cancer cell lines and primary tumors [<CitationRef CitationID="CR18">18</CitationRef>–<CitationRef CitationID="CR20">20</CitationRef>]. In our study, <Emphasis Type="Italic">DLEC1</Emphasis> revealed the highest frequency of decreased expression. Additionally, the differences between NSCLC and paired macroscopically unchanged lung tissue were significant: <Emphasis Type="Italic">DLEC1</Emphasis> expression was significantly lower in tumor specimens.</Para>
              <Para ID="Par34">
                        <Emphasis Type="Italic">DLEC1</Emphasis> promoter hypermethylation is responsible for its silencing, as found in a variety of human cancers. Indeed, epigenetic silencing of <Emphasis Type="Italic">DLEC1</Emphasis> was found to be specific for cancerous lung tissue, as it was only rarely detected in matched normal lung tissue [<CitationRef CitationID="CR18">18</CitationRef>, <CitationRef CitationID="CR20">20</CitationRef>]. In NSCLC primary lesions and cell lines, <Emphasis Type="Italic">DLEC1</Emphasis> methylation was observed in 27–56 % of samples [<CitationRef CitationID="CR18">18</CitationRef>–<CitationRef CitationID="CR21">21</CitationRef>] and in most cases correlated with decreased gene expression [<CitationRef CitationID="CR18">18</CitationRef>–<CitationRef CitationID="CR20">20</CitationRef>]. In our study, we observed <Emphasis Type="Italic">DLEC1</Emphasis> methylation in 84 % of NSCLCs, and the simultaneous promoter methylation and gene decreased expression were found in 63 % of lung tumor samples. Gene methylation level was moderate, showing higher level in SCC (30 %) than in NSCC (19 %), although the difference was not statistically significant. In several studies, gene promoter hypermethylation was associated with poorer prognosis in NSCLC patients [<CitationRef CitationID="CR18">18</CitationRef>, <CitationRef CitationID="CR20">20</CitationRef>, <CitationRef CitationID="CR21">21</CitationRef>]. The study conducted by Seng et al. [<CitationRef CitationID="CR20">20</CitationRef>] showed that epigenetic silencing of the gene was tightly connected with II grade tumors and lymph node metastasis, as well as shorter survival time. However, the findings are conflicting [<CitationRef CitationID="CR21">21</CitationRef>]. In our study, significantly higher <Emphasis Type="Italic">DLEC1</Emphasis> methylation level was associated with T2 tumors in SCC group and stage I in NSCC group. It could indicate the role of gene epigenetic modification in lung cancer initiation rather than in progression.</Para>
              <Para ID="Par35">In others’ studies, there were not any associations between the methylation status of <Emphasis Type="Italic">DLEC1</Emphasis> and pathological stages, lymph node metastasis, tumor squamous histology, patients’ smoking status, age and gender [<CitationRef CitationID="CR18">18</CitationRef>, <CitationRef CitationID="CR21">21</CitationRef>]. We found significant correlation between <Emphasis Type="Italic">DLEC1</Emphasis> methylation and patients’ age, indicating its higher level in older NSCLC patients. It is in line with negative correlation observed between <Emphasis Type="Italic">DLEC1</Emphasis> expression level and patients’ age in SCC subgroup.</Para>
              <Para ID="Par36">Interesting finding regarding <Emphasis Type="Italic">DLEC1</Emphasis> methylation in lung cancer was its good correlation with gene methylation status in patients’ plasma, as found by Zhang et al. [<CitationRef CitationID="CR18">18</CitationRef>]. Summing up, <Emphasis Type="Italic">DLEC1</Emphasis> methylation could be regarded as a common event contributing to NSCLC initiation and progression. It provides a potential biomarker that could be a constituent of the methylation-based panel for NSCLC diagnosis and prognosis.</Para>
              <Para ID="Par37">Such panel might include also another studied TSG, <Emphasis Type="Italic">ITGA9</Emphasis> (<Emphasis Type="Italic">integrin, alpha 9</Emphasis>). Gene decreased expression in NSCLC was demonstrated, and the possible mechanism responsible for its silencing was methylation and/or deletion [<CitationRef CitationID="CR7">7</CitationRef>, <CitationRef CitationID="CR22">22</CitationRef>]. In our study, importantly decreased <Emphasis Type="Italic">ITGA9</Emphasis> expression was observed in 36 % of NSCLC samples and more frequently in SCC (50 %) as compared to NSCC (16 %). This is in accordance with the results of others [<CitationRef CitationID="CR7">7</CitationRef>], on the basis of which <Emphasis Type="Italic">ITGA9</Emphasis> was incorporated into the panel of 19 markers that allowed early detection, tumor progression, metastases and discrimination between SCC and AC. In our study, we confirmed statistically significant differences in gene expression between the histopathological subtypes, with significantly lower <Emphasis Type="Italic">ITGA9</Emphasis> expression in SCC. Gene promoter methylation—which could be responsible for gene silencing in lung tumor—was observed in 57 % of NSCLC samples, and its methylation level ranged from 25 to 37 %, depending on the histotype. The simultaneous gene decreased expression and promoter hypermethylation were revealed in 52 % of SCC samples (data not shown); however, we did not observe statistically significant correlations between RQ and MI values.</Para>
              <Para ID="Par38">To the best of our knowledge, there are no other available reports on <Emphasis Type="Italic">ITGA9</Emphasis> in lung cancer. <Emphasis Type="Italic">ITGA9</Emphasis> is an interesting gene, and it encodes a component of the α9β1 integrin receptor that plays an integral role in different signal transduction pathways, controlling cellular proliferation and differentiation [<CitationRef CitationID="CR23">23</CitationRef>]. However, the data regarding <Emphasis Type="Italic">ITGA9</Emphasis> expression in cancers are conflicting [<CitationRef CitationID="CR24">24</CitationRef>, <CitationRef CitationID="CR25">25</CitationRef>]. Our results resemble those obtained by Mostovich et al. [<CitationRef CitationID="CR25">25</CitationRef>] in breast cancer, especially in AC group in which <Emphasis Type="Italic">ITGA9</Emphasis> expression was decreased in one half of samples and increased in the second half of specimens (data not shown). In SCC group—in all samples except two—gene expression was reduced. The heterogenous status of <Emphasis Type="Italic">ITGA9</Emphasis> expression in lung tumors could be the basis for their differentiation and gene considered as diagnostic marker. It is strengthened by our finding of its significantly lower expression level in lung tumor specimens as compared to macroscopically unchanged lung tissue.</Para>
              <Para ID="Par39">The third studied gene, <Emphasis Type="Italic">MLH1</Emphasis> (<Emphasis Type="Italic">mutL homolog 1</Emphasis>), belongs to a mismatch repair (MMR) system and plays a pivotal role in maintaining genome stability, including microsatellite instability (MSI) and the accumulation of gene mutations associated with carcinogenesis. The studies indicated LOH and promoter methylation as main mechanisms of <Emphasis Type="Italic">MLH1</Emphasis> decreased expression in various cancers [<CitationRef CitationID="CR26">26</CitationRef>, <CitationRef CitationID="CR27">27</CitationRef>]. However, regarding methylation status of <Emphasis Type="Italic">MLH1</Emphasis>, the reported frequencies in NSCLC are very different, ranging from 0 to 72 % [<CitationRef CitationID="CR20">20</CitationRef>, <CitationRef CitationID="CR26">26</CitationRef>, <CitationRef CitationID="CR28">28</CitationRef>–<CitationRef CitationID="CR30">30</CitationRef>]. Our analysis revealed frequent promoter methylation of <Emphasis Type="Italic">MLH1</Emphasis> (84 % of NSCLC samples) and the methylation level of the gene in the range of 27–34 %. Additionally, significantly higher <Emphasis Type="Italic">MLH1</Emphasis> methylation was found in stage I/II SCC samples as compared to stage III. It could suggest the role of epigenetic modifications of <Emphasis Type="Italic">MLH1</Emphasis> at early stages of lung carcinogenesis. In other studies, analyzing patient survival rates, strong association between gene methylation and poor prognosis in NSCLC was observed [<CitationRef CitationID="CR20">20</CitationRef>, <CitationRef CitationID="CR31">31</CitationRef>].</Para>
              <Para ID="Par40">Similarly to <Emphasis Type="Italic">MLH1</Emphasis> methylation results in different studies, the reports on its expression are ambiguous. Geng et al. [<CitationRef CitationID="CR26">26</CitationRef>] reported high, almost equal in frequencies, methylation (72 %) and loss of expression (68 %) of <Emphasis Type="Italic">MLH1</Emphasis> in Chinese population. In other studies, despite high (72 % in SCC) or moderate (35 %) methylation level, loss of MLH1 protein expression was rare, suggesting that <Emphasis Type="Italic">MLH1</Emphasis> promoter methylation does not usually lead to gene silencing in lung cancer [<CitationRef CitationID="CR20">20</CitationRef>, <CitationRef CitationID="CR32">32</CitationRef>]. Similarly, in our study, <Emphasis Type="Italic">MLH1</Emphasis> expression was not importantly decreased, as found only in 3.4–5.9 % of the tumor samples, depending on the histotype. The simultaneous decreased gene expression and gene promoter hypermethylation occurred only in three NSCLC samples.</Para>
              <Para ID="Par41">In general, we found median values of <Emphasis Type="Italic">MLH1</Emphasis> expression levels similar in tumor and macroscopically unchanged lung tissue groups. The overexpression of <Emphasis Type="Italic">MLH1</Emphasis> on protein level (especially in AC subtype) was also found by Li et al. [<CitationRef CitationID="CR33">33</CitationRef>], who concluded that other genetic lesions—such as EGFR mutations—might be earlier events and could occur before MLH1 disturbed expression pattern in lung carcinogenesis.</Para>
            </Section1>
            <Section1 ID="Sec14">
              <Heading>Conclusions</Heading>
              <Para ID="Par42">In our analysis, the expression levels of <Emphasis Type="Italic">DLEC1</Emphasis> and <Emphasis Type="Italic">ITGA9</Emphasis> were prominently decreased in lung tumor samples. Their significant differences—when compared with macroscopically unchanged lung tissue surrounding primary lesions—highlight the role of those TSGs in lung carcinogenesis. Additionally, <Emphasis Type="Italic">ITGA9</Emphasis> could be regarded as diagnostic markers differentiating NSCLC histopathological subtypes, and—similarly to <Emphasis Type="Italic">DLEC1</Emphasis>—distinguishing lung cancerous and macroscopically unchanged tissue.</Para>
              <Para ID="Par43">Promoter methylation analysis pointed to the epigenetic modifications of all three studied genes and their significance in lung carcinogenesis. Their simultaneous methylation in more than 50 % of NSCLC samples might suggest the possibility of considering them as a panel of epigenetic markers. Confirmation of such hypothesis requires further study. Perhaps in the future, these genes become targets for novel possible epigenetic drugs.</Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/12032_2016_Article_791.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Acknowledgments>
              <Heading>Acknowledgments</Heading>
              <SimplePara>This work was supported by the Grant of the National Science Centre, Poland, No. 2011/01/B/NZ4/04966.</SimplePara>
              <FormalPara ID="FPar1" RenderingStyle="Style1">
                <Heading>Authors’ contribution</Heading>
                <Para ID="Par44">Dorota Pastuszak-Lewandoska and Jacek Kordiak have equally contributed to this work.</Para>
              </FormalPara>
            </Acknowledgments>
            <Ethics>
              <Heading>Compliance with ethical standards</Heading>
              <FormalPara ID="FPar2" RenderingStyle="Style1">
                <Heading>Conflict of interest</Heading>
                <Para ID="Par45">The authors declare no conflict of interest.</Para>
              </FormalPara>
            </Ethics>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Jemal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Bray</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MM</Initials>
                    <FamilyName>Center</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Ferlay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Ward</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Forman</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Global cancer statistics</ArticleTitle>
                  <JournalTitle>CA Cancer J Clin</JournalTitle>
                  <VolumeID>61</VolumeID>
                  <FirstPage>69</FirstPage>
                  <LastPage>90</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.3322/caac.20107</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21296855</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Hassanein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JC</Initials>
                    <FamilyName>Callison</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Callaway-Lane</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MC</Initials>
                    <FamilyName>Aldrich</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EL</Initials>
                    <FamilyName>Grogan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PP</Initials>
                    <FamilyName>Massion</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">The state of molecular biomarkers for the early detection of lung cancer</ArticleTitle>
                  <JournalTitle>Cancer Prev Res (Phila)</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>992</FirstPage>
                  <LastPage>1006</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhsVSmtbrM</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/1940-6207.CAPR-11-0441</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila). 2012;5:992–1006.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LB</Initials>
                    <FamilyName>Hesson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WN</Initials>
                    <FamilyName>Cooper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Latif</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Evaluation of the 3p21.3 tumour-suppressor gene cluster</ArticleTitle>
                  <JournalTitle>Oncogene</JournalTitle>
                  <VolumeID>26</VolumeID>
                  <FirstPage>7283</FirstPage>
                  <LastPage>7301</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhtlWjtrzM</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.onc.1210547</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17533367</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007;26:7283–301.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MI</Initials>
                    <FamilyName>Lerman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JD</Initials>
                    <FamilyName>Minna</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The international lung cancer chromosome 3p21.3 tumor suppressor gene consortium</ArticleTitle>
                  <JournalTitle>Cancer Res</JournalTitle>
                  <VolumeID>60</VolumeID>
                  <FirstPage>6116</FirstPage>
                  <LastPage>6133</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXotV2lsbw%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11085536</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The international lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res. 2000;60:6116–33.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>II</Initials>
                    <FamilyName>Wistuba</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Behrens</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Virmani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Mele</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Milchgrub</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Girard</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints</ArticleTitle>
                  <JournalTitle>Cancer Res</JournalTitle>
                  <VolumeID>60</VolumeID>
                  <FirstPage>1949</FirstPage>
                  <LastPage>1960</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXisVynu7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>10766185</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000;60:1949–60.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>VN</Initials>
                    <FamilyName>Senchenko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Loginov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Bazov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Angeloni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Seryogin</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas</ArticleTitle>
                  <JournalTitle>Oncogene</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <FirstPage>5719</FirstPage>
                  <LastPage>5728</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXmtVCnsLo%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.onc.1207760</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15208675</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, Seryogin Y, et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene. 2004;23:5719–28.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AA</Initials>
                    <FamilyName>Dmitriev</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VI</Initials>
                    <FamilyName>Kashuba</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Haraldson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VN</Initials>
                    <FamilyName>Senchenko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TV</Initials>
                    <FamilyName>Pavlova</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AV</Initials>
                    <FamilyName>Kudryavtseva</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays</ArticleTitle>
                  <JournalTitle>Epigenetics</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>502</FirstPage>
                  <LastPage>513</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhtFCjsb3I</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.4161/epi.19801</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22491060</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dmitriev AA, Kashuba VI, Haraldson K, Senchenko VN, Pavlova TV, Kudryavtseva AV, et al. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics. 2012;7:502–13.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>ER</Initials>
                    <FamilyName>Zabarovsky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MI</Initials>
                    <FamilyName>Lerman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JD</Initials>
                    <FamilyName>Minna</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers</ArticleTitle>
                  <JournalTitle>Oncogene</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>6915</FirstPage>
                  <LastPage>6935</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XnsVKrurg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.onc.1205835</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12362274</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 2002;21:6915–35.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Pastuszak-Lewandoska</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Kordiak</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Migdalska-Sęk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KH</Initials>
                    <FamilyName>Czarnecka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Antczak</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Górski</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients</ArticleTitle>
                  <JournalTitle>Respir Res</JournalTitle>
                  <VolumeID>16</VolumeID>
                  <FirstPage>76</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/s12931-015-0230-6</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>26112163</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4484633</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Pastuszak-Lewandoska D, Kordiak J, Migdalska-Sęk M, Czarnecka KH, Antczak A, Górski P, et al. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients. Respir Res. 2015;16:76.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Esteller</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Epigenetics in cancer</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>358</VolumeID>
                  <FirstPage>1148</FirstPage>
                  <LastPage>1159</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXjt1ahs7Y%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJMra072067</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18337604</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–59.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DG</Initials>
                    <FamilyName>Burbee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Forgacs</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Zöchbauer-Müller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Shivakumar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Fong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Gao</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression</ArticleTitle>
                  <JournalTitle>J Natl Cancer Inst</JournalTitle>
                  <VolumeID>93</VolumeID>
                  <FirstPage>691</FirstPage>
                  <LastPage>699</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXjvVamu7o%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/jnci/93.9.691</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11333291</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4374741</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001;93:691–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Toyooka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Suzuki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Maruyama</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KO</Initials>
                    <FamilyName>Toyooka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Tsukuda</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Fukuyama</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">The relationship between aberrant methylation and survival in non-small-cell lung cancers</ArticleTitle>
                  <JournalTitle>Br J Cancer</JournalTitle>
                  <VolumeID>91</VolumeID>
                  <FirstPage>771</FirstPage>
                  <LastPage>774</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXmsVCgsbw%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15266335</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2364802</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1038/sj.bjc.6602013</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer. 2004;91:771–4.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Zöchbauer-Müller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KM</Initials>
                    <FamilyName>Fong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Virmani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Geradts</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AF</Initials>
                    <FamilyName>Gazdar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JD</Initials>
                    <FamilyName>Minna</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Aberrant promoter methylation of multiple genes in non-small cell lung cancers</ArticleTitle>
                  <JournalTitle>Cancer Res</JournalTitle>
                  <VolumeID>61</VolumeID>
                  <FirstPage>249</FirstPage>
                  <LastPage>255</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11196170</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249–55.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Heller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Zielinski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Zöchbauer-Müller</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Lung cancer: from single-gene methylation to methylome profiling</ArticleTitle>
                  <JournalTitle>Cancer Metastasis Rev</JournalTitle>
                  <VolumeID>29</VolumeID>
                  <FirstPage>95</FirstPage>
                  <LastPage>107</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXitVOjtL8%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s10555-010-9203-x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20099008</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Heller G, Zielinski CC, Zöchbauer-Müller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 2010;29:95–107.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>FA</Initials>
                    <FamilyName>Feltus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EK</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JF</Initials>
                    <FamilyName>Costello</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Plass</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PM</Initials>
                    <FamilyName>Vertino</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Predicting aberrant CpG island methylation</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>100</VolumeID>
                  <FirstPage>12253</FirstPage>
                  <LastPage>12258</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXotlGks74%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.2037852100</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>14519846</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>218745</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. Predicting aberrant CpG island methylation. Proc Natl Acad Sci USA. 2003;100:12253–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LC</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Dahiya</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">MethPrimer: designing primers for methylation PCRs</ArticleTitle>
                  <JournalTitle>Bioinformatics</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>1427</FirstPage>
                  <LastPage>1431</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XosFOhtb0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/bioinformatics/18.11.1427</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12424112</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427–31.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Liloglou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NG</Initials>
                    <FamilyName>Bediaga</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BR</Initials>
                    <FamilyName>Brown</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JK</Initials>
                    <FamilyName>Field</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MP</Initials>
                    <FamilyName>Davies</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Epigenetic biomarkers in lung cancer</ArticleTitle>
                  <JournalTitle>Cancer Lett</JournalTitle>
                  <VolumeID>342</VolumeID>
                  <FirstPage>200</FirstPage>
                  <LastPage>212</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XntlSnsLk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.canlet.2012.04.018</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22546286</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014;342:200–12.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Miao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Yi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer</ArticleTitle>
                  <JournalTitle>Clin Lung Cancer</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>264</FirstPage>
                  <LastPage>270</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXpvVegs7s%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.3816/CLC.2010.n.034</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20630829</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zhang Y, Miao Y, Yi J, Wang R, Chen L. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Clin Lung Cancer. 2010;11:264–70.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Rauch</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GP</Initials>
                    <FamilyName>Pfeifer</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain- containing genes in lung cancer cells</ArticleTitle>
                  <JournalTitle>Cancer Res</JournalTitle>
                  <VolumeID>66</VolumeID>
                  <FirstPage>7939</FirstPage>
                  <LastPage>7947</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XotFWqtrs%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/0008-5472.CAN-06-1888</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16912168</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rauch T, Li H, Wu X, Pfeifer GP. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain- containing genes in lung cancer cells. Cancer Res. 2006;66:7939–47.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TJ</Initials>
                    <FamilyName>Seng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Currey</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WA</Initials>
                    <FamilyName>Cooper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CS</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Chan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Horvath</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma</ArticleTitle>
                  <JournalTitle>Br J Cancer</JournalTitle>
                  <VolumeID>99</VolumeID>
                  <FirstPage>375</FirstPage>
                  <LastPage>382</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXosFWntrg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.bjc.6604452</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18594535</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2480971</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer. 2008;99:375–82.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Sasaki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Hikosaka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>O</Initials>
                    <FamilyName>Kawano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Moriyama</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Yano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Fujii</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients</ArticleTitle>
                  <JournalTitle>Oncol Lett.</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>283</FirstPage>
                  <LastPage>287</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXktVWnurs%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22966295</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3436471</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.3892/ol_00000050</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y. Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients. Oncol Lett. 2010;1:283–7.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EA</Initials>
                    <FamilyName>Anedchenko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AA</Initials>
                    <FamilyName>Dmitriev</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GS</Initials>
                    <FamilyName>Krasnov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TT</Initials>
                    <FamilyName>Kondrat’eva</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EP</Initials>
                    <FamilyName>Kopantsev</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TV</Initials>
                    <FamilyName>Vinogradova</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer</ArticleTitle>
                  <JournalTitle>Mol Biol (Mosk)</JournalTitle>
                  <VolumeID>42</VolumeID>
                  <FirstPage>965</FirstPage>
                  <LastPage>976</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD1M%2FmvVKgtw%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1134/S0026893308060058</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Anedchenko EA, Dmitriev AA, Krasnov GS, Kondrat’eva TT, Kopantsev EP, Vinogradova TV, et al. Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer. Mol Biol (Mosk). 2008;42:965–76.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Høye</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Couchman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>UM</Initials>
                    <FamilyName>Wewer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Fukami</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Yoneda</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">The newcomer in the integrin family: integrin α9 in biology and cancer</ArticleTitle>
                  <JournalTitle>Adv Biol Regul</JournalTitle>
                  <VolumeID>52</VolumeID>
                  <FirstPage>326</FirstPage>
                  <LastPage>339</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.jbior.2012.03.004</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22781746</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Høye AM, Couchman JR, Wewer UM, Fukami K, Yoneda A. The newcomer in the integrin family: integrin α9 in biology and cancer. Adv Biol Regul. 2012;52:326–39.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Hibi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Yamakawa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Ueda</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Horio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Murata</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Tamari</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer</ArticleTitle>
                  <JournalTitle>Oncogene</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>611</FirstPage>
                  <LastPage>619</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXisVWnsL8%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>8290272</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hibi K, Yamakawa K, Ueda R, Horio Y, Murata Y, Tamari M, et al. Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer. Oncogene. 1994;9:611–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LA</Initials>
                    <FamilyName>Mostovich</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TY</Initials>
                    <FamilyName>Prudnikova</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AG</Initials>
                    <FamilyName>Kondratov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Loginova</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PV</Initials>
                    <FamilyName>Vavilov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VI</Initials>
                    <FamilyName>Rykova</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors</ArticleTitle>
                  <JournalTitle>Cell Adhes Migr</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>395</FirstPage>
                  <LastPage>401</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.4161/cam.5.5.17949</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mostovich LA, Prudnikova TY, Kondratov AG, Loginova D, Vavilov PV, Rykova VI, et al. Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors. Cell Adhes Migr. 2011;5:395–401.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Geng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WM</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL Homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population</ArticleTitle>
                  <JournalTitle>Tumori</JournalTitle>
                  <VolumeID>95</VolumeID>
                  <FirstPage>488</FirstPage>
                  <LastPage>494</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXhtlGntrvE</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19856662</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Geng X, Wang F, Zhang L, Zhang WM. Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL Homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population. Tumori. 2009;95:488–94.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Bischoff</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Ignatov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Semczuk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Schwarzenau</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Ignatov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Krebs</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases</ArticleTitle>
                  <JournalTitle>Clin Exp Metastasis</JournalTitle>
                  <VolumeID>29</VolumeID>
                  <FirstPage>889</FirstPage>
                  <LastPage>900</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhslaqurjE</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s10585-012-9478-0</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22552371</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bischoff J, Ignatov A, Semczuk A, Schwarzenau C, Ignatov T, Krebs T, et al. hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis. 2012;29:889–900.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Safar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Spencer</FamilyName>
                    <Suffix>3rd</Suffix>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Su</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Coffey</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Cooney</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LD</Initials>
                    <FamilyName>Ratnasinghe</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Methylation profiling of archived non-small cell lung cancer: a promising prognostic system</ArticleTitle>
                  <JournalTitle>Clin Cancer Res</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>4400</FirstPage>
                  <LastPage>4405</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXltFeksr0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/1078-0432.CCR-04-2378</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15958624</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res. 2005;11:4400–5.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Tang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Torres-Lanzas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Lopez-Rios</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Esteller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Sanchez-Cespedes</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung</ArticleTitle>
                  <JournalTitle>Int J Cancer</JournalTitle>
                  <VolumeID>119</VolumeID>
                  <FirstPage>2603</FirstPage>
                  <LastPage>2609</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhtFygtbfE</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/ijc.22211</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16991125</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tang M, Torres-Lanzas J, Lopez-Rios F, Esteller M, Sanchez-Cespedes M. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer. 2006;119:2603–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>YC</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YP</Initials>
                    <FamilyName>Lu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RC</Initials>
                    <FamilyName>Tseng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RK</Initials>
                    <FamilyName>Lin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JW</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples</ArticleTitle>
                  <JournalTitle>J Clin Invest</JournalTitle>
                  <VolumeID>111</VolumeID>
                  <FirstPage>887</FirstPage>
                  <LastPage>895</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXitlOjtrg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1172/JCI15475</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12639995</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>153761</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 2003;111:887–95.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HS</Initials>
                    <FamilyName>Hsu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CK</Initials>
                    <FamilyName>Wen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YA</Initials>
                    <FamilyName>Tang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RK</Initials>
                    <FamilyName>Lin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WY</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WH</Initials>
                    <FamilyName>Hsu</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer</ArticleTitle>
                  <JournalTitle>Clin Cancer Res</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>5410</FirstPage>
                  <LastPage>5416</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXmvFSmtb4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1158/1078-0432.CCR-05-0601</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16061855</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hsu HS, Wen CK, Tang YA, Lin RK, Li WY, Hsu WH, et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res. 2005;11:5410–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Gomes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Reis-Silva</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Alarcão</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Couceiro</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Sousa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Carvalho</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung</ArticleTitle>
                  <JournalTitle>Rev Port Pneumol</JournalTitle>
                  <VolumeID>20</VolumeID>
                  <FirstPage>20</FirstPage>
                  <LastPage>30</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BC2c3ptFGjsg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.rppneu.2013.07.003</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24360395</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gomes A, Reis-Silva M, Alarcão A, Couceiro P, Sousa V, Carvalho L. Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Rev Port Pneumol. 2014;20:20–30.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Q</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Lu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Wei</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RW</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations</ArticleTitle>
                  <JournalTitle>PLoS One</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>e78500</FirstPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXhslWgsb3N</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1371/journal.pone.0078500</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24205245</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3812034</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Li M, Zhang Q, Liu L, Lu W, Wei H, Li RW, et al. Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations. PLoS One. 2013;8:e78500.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
